key: cord-0738022-gqy7v8zl authors: Salehi-Vaziri, Mostafa; Pouriayevali, Mohammad Hassan; Fotouhi, Fatemeh; Jalali, Tahmineh; Banifazl, Mohammad; Farahmand, Behrokh; Larijani, Mona Sadat; Ahmadi, Zahra; Fereydouni, Zahra; Tavakoli, Mahsa; Karami, Afsaneh; Azad-Manjiri, Sanam; Sanati, Parastoo Yektay; Dahmardeh, Sarah; Nemati, Amir Hesam; Sajadi, Marzyie; Kashanian, Setareh; Ramezani, Amitis title: SARS-CoV-2 Re-infection rate in Iranian COVID-19 cases within one-year follow-up date: 2021-11-18 journal: Microb Pathog DOI: 10.1016/j.micpath.2021.105296 sha: e21f50acad7243d2c4b51bf76db550b767528da3 doc_id: 738022 cord_uid: gqy7v8zl Since the COVID-19 pandemic initiation, the possibility of re-infection has been unclearly present. Although herd immunity has a potential reliance through natural infection, human corona viruses has the ability to subvert immunity and re-infection happens for seasonal corona viruses. Currently, the frequency of SARS-CoV-2 re-infection incidence is not exactly defined. In this study we aimed at determination of SARS-CoV-2 re-infection rate in Iranian population. In a total of 5696 COVID-19 suspicious individuals, RT-PCR was applied to diagnose the infection. The confirmed patients were followed for 12 months and serology tests were applied to measure the specific antibodies. Among 1492 confirmed COVID-19 cases, five individuals experienced the subsequent infection. The re-infection/reactivation incidence rate was totally 0.33% after one year of follow-up. The interval ranged from 63 to 156 days. All the cases had viral mutations in the second episode of the infection. All of them were symptomatic cases with moderate severity. The estimated rate of SARS-CoV-2 in Persian population is therefore rare and natural infection seems to induce good protection against re-infection which clear that mass vaccination could hugely affect the society. Cases Within One-year Follow-up" is proudly being submitted to your valuable journal. All Authors declare that: The manuscript has been prepared originally by authors, otherwise the sources have been cited and reprint permission is attached. -The manuscript has not been and will not be published elsewhere or submitted elsewhere for publication. -Authors mention that there is no conflict of interest in this study. * We declare that all individual authors are not on any of the (http://data.europa.eu/euodp/en/data/dataset/consolidated-list-of-persons-groups-and-entitiessubject-to-eu-financial-sanctions, http://hmt-sanctions. -SARS-CoV-2 re-infections are mostly well tolerated and no more symptomatic than first infections. -The evaluation of SARS-CoV-2 re-infection will help to find an appropriate solution to prevent re-infection. Since the COVID-19 pandemic initiation, the possibility of re-infection has been unclearly present. Although herd immunity has a potential reliance through natural infection, human corona viruses has the ability to subvert immunity and re-infection happens for seasonal corona viruses. Currently, the frequency of SARS-CoV-2 re-infection incidence is not exactly defined. In this study we aimed at determination of SARS-CoV-2 re-infection rate in Iranian population. In a total of 5696 COVID-19 suspicious individuals, RT-PCR was applied to diagnose the infection. The confirmed patients were followed for 12 months and serology tests were applied to measure the specific antibodies. Among 1492 confirmed COVID-19 cases, five individuals experienced the subsequent infection. The re-infection/reactivation incidence rate was totally 0.33% after one year of follow-up. The interval ranged from 63 to 156 days. All the cases had viral mutations in the second episode of the infection. All of them were symptomatic cases with moderate severity. The estimated rate of SARS-CoV-2 in Persian population is therefore rare and natural infection seems to induce good protection against re-infection which clear that mass vaccination could hugely affect the society. A true diagnosis of SARS-CoV-2 re-infection must be established when complete viral clearance is achieved after the first episode of infection. Moreover, sufficient time is needed to allow for mounted immune responses [6] . The studies which focus on characterizing COVID-19-related immunity have shown that binding and neutralizing antibodies developed in response to SARS-CoV-2 infection and could provide protection up to six months after the onset of symptoms. Antibody titers establishment as a correlated factor with protection should be defined as a protective element which would be extremely critical for both patient management and public health considerations [7, 8] . In fact, the importance of re-infection determination in a community can reflect the quarantine policy and vaccine development strategies. Although the cause of SARS-CoV-2 re-infection/reactivation has not been fully characterized, some factors were found to be associated with its possibility including age and underlying diseases [9] . What is more, a study on a large population has revealed that individuals who once experienced COVID-19, had J o u r n a l P r e -p r o o f lower re-infection and symptomatic infection risks of 84% and 93% respectively within 7 months of follow-up [10] . The rates of protection against subsequent infections of SARS-CoV-2 is still little known although some studies suggest that SARS-CoV-2 re-infection occurs in less than 1% of those who previously were positive for SARS-CoV-2 [11, 12] . Nevertheless, most of the findings are based on several single or small case studies. Therefore, determination of the re-infection rate in large population can contribute to a better understanding. In other words, more epidemiological case definition of SARSCoV-2 re-infection is crucial to strengthen community surveillance. In this study, determination of COVID-19 re-infection rate among Iranian population was investigated. In this study, 5696 COVID-19 suspected cases were enrolled and studied at COVID-19 National Symptomatic cases were considered for molecular and serological tests for COVID-19. Considering both re-infection and viral reactivation, the subsequent infection was recorded for five individuals, 0.33%, among all from whom four were males and one was female ranging from 32 to 54 years old. The interval between the two episodes ranged from 63 to 156 days. The sequencing results showed different mutation patterns between first and second episodes in two cases indicating the occurrence of re-infection (No.4, 5) (Table 1) . By the way in two subjects (No.1, 3) we had no access to first sample but D614G mutation was detected in second time. According to the time of first infection, the predominant circulating virus was D614 and few months later, G614 type became dominant in our country then we supposed these cases as possibly re-infected (Table 1) . One case sequencing revealed L139L non-synonymous mutation in both episodes that was assessed as a SARS-CoV-2 reactivated case. Moreover, four cases were found IgG positive in the re-infection phase except one whose full viral sequencing showed 6 new mutations in the second episode in comparison with the first incidence [14, 15] . All of them were symptomatic cases with moderate severity except one case who presented with mild infection in first episode and moderate infection with lung involvement in second time (case No.5). Therefore, re-infections mostly were well tolerated and no more symptomatic than first infections. presentations, and SARS-CoV-2 RT-PCR tests positive but probably due to the low quality of samples and high cycle threshold, these cases were not confirmed and documented by viral genome sequencing as re-infection individuals. J o u r n a l P r e -p r o o f The possibility of SARS-CoV-2 re-infection or reactivation can significantly reflect clinical implications and also vaccination strategy. In the present study, we assessed the frequency of SARS-CoV-2 re-infection/reactivation in Iranian population according to a long term follow-up and the previous studies on re-infection case reports. This study showed that the documented subsequent infection in our population is 0.33% which can be defined as a rare incidence. All of them were symptomatic cases with moderate severity. Our results suggested that re-infections are mostly well tolerated and no more symptomatic than first infections. In a study which was done on 3249 participants from the U.S, 189 individuals were seropositive from whom 10% had at least one SARS-CoV-2 positive PCR test during the 6-week follow-up. In contrast, 48% of the seronegative individuals tested positive and the incidence rate ratio was assessed 0.18. Moreover, among the seropositive cases with lower baseline of spike protein IgG titers, infection rate was more than in those who had higher baseline of SIgG titers [16] . SARS-CoV-2 re-infection investigate in India revealed the rate of 4.5% (58 out of 1300 cases). Furthermore, the vast majority of the participants was asymptomatic and showed higher Ct value during the first infection. [17] . The other survey which was done in Denmark showed that 0.65% of the confirmed COVID-19 cases in the first incidence reached positive PCR again after the follow-up. In comparison those who were PCR negative in the first step of the study, 3.27% developed the infection during the follow-up. Therefore, they found that protection against re-infection was 80.5%. Moreover, age was found an important factor for repeated infection as protection was 47.1%among those older than 65 years [18] . The other study by Abu-Raddad et al. on 43,044 positive cases who were followed for about 4 months, 0.7% individuals had a second positive PCR two weeks after the positive serology test. From this population 41% had epidemiological lines of evidence for the re-infection. The final sequencing assessment recorded 0.1% re-infection rate in the investigated population in Qatar [19] . Most of Re-infection cases were mildly symptomatic and 1 severe and 2 moderate subjects found. These results suggested that most of re-infections had well tolerated condition. Pilz et al. reported low re-infection rate of SARS-CoV-2 in Austria. These findings showed natural infection seems to induce strong protection against re-infection which is comparable with vaccine efficacious Austria. Our study is compatible with other investigations regarding scarce rate of SARS-CoV-2 reinfections. During the COVID-19 infection, the induced antibodies by initial infection can be largely protective. However, they might not guarantee preventive SARS-CoV-2 further immunity against subsequent infection. These findings from different population can be practical for mass vaccination strategies. Although SARS-CoV-2 re-infection has been still a rare phenomenon, the epidemiological definition of re-infection is required for surveillance establishment and this study contributes to such an essential goal. A limitation of the current study is that the few cases were not confirmed and recorded as reinfected individuals by viral genome sequencing due to low sample quality and high cycle threshold. Re-infection with SARS-CoV-2: considerations for public health response What re-infection s mean for COVID-19. The Lancet Infectious Diseases Genomic evidence for re-infection with SARS-CoV-2: a case study Covid-19: Hong Kong scientists report first confirmed case of re-infection Re-infection with SARS-CoV-2: implementation of a surveillance case definition within the EU/EEA SARS-CoV-2, a virus with many faces: a series of cases with prolonged persistence of COVID-19 symptoms Prolonged Viral Shedding and Antibody Persistence in Patients with COVID-19. Microbes and Infection. 2021:104810. 9. Researchers identify risk factors for SARS-CoV-2 re-infection SARS-CoV-2 infection rates of antibodypositive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). The Lancet SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study Clinical Characteristics of SARS-CoV-2 by Re-infection Vs. Reactivation: A Case Series From Iran SARS-CoV-2 presented moderately during two episodes of the infection with lack of antibody responses SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study. The Lancet Respiratory Medicine SARS-CoV-2 re-infection: development of an epidemiological definition from India Assessment of protection against re-infection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study SARS-CoV-2 re-infection in a cohort of 43,000 antibody-positive individuals followed for up to 35 weeks SARS-CoV-2 re-infection risk in Austria We appreciate the Pasteur Institute of Iran for the financial support of this study.